KRAS and lung carcinoma: In this regard, mutation of certain lung cancer “driver” genes such as TP53, KRAS and CDKN2A was also associated with altered expression of ACOX2 in both LUAD and LUSC (Table 2) suggesting that cohorts of patients with such mutations could have altered peroxisomal pathways that may play a role in tumorigenesis.